Do You Always Call Out Typos? Science Says You’re the Worst

Does your skin crawl whenever you spot a dangling modifier, or “its” in place of “it’s”? If so, you’re probably not going to like this new research from the University of Michigan.

The small study—titled “If You’re House Is Still Available, Send Me an Email” (see what they did there?)— explores which personality types are most sensitive to grammar mistakes. The researchers had 83 people read emails with typos (such as “teh” vs. “the”), grammar errors (like “there” vs. “they’re”), or no mistakes. After reading all the emails, participants were asked if they’d spotted any errors and, if so, how much it irritated them.

Next, the researchers considered the subjects’ dispositions. Participants were asked to complete the Big Five personality assessment (which determines a person’s level of extraversion, agreeability, conscientiousness, neuroticism, and openness). They were also asked to judge the writers of the emails, by rating them on traits like intelligence and friendliness.

RELATED: 10 Ways Your Personality Affects Your Weight

The (perhaps unsurprising) results? Subjects with personalities deemed “less agreeable” were more irritated by errors than other participants. The researchers believe it’s because people with this personality type are “less tolerant of deviations from convention”—which appears to be a nicer way of saying members of the grammar police are kind of jerks.

They also found that extroverts were more likely to breeze past spelling and grammar errors, while introverts tended to notice mistakes and negatively judge the writer who made them. Meanwhile, people who scored high on conscientiousness and low on openness were more sensitive to typos. Yet, how neurotic someone was appeared to have no affect on the way they detected and interpreted mistakes.

RELATED: 15 Ways Being an Introvert Can Affect Your Health

Some people (including Health‘s entire editorial staff) find this study a bit insulting. But since the sample size was slim, we’re taking the findings with a grain of salt until further research backs up the claims.

 

from Health News / Tips & Trends / Celebrity Health http://ift.tt/1RO13xJ

Scientists Reduce Alzheimer’s-Linked Brain Plaques in Mice

By Randy Dotinga
HealthDay Reporter

THURSDAY, March 31, 2016 (HealthDay News) — Scientists working with mice report preliminary progress in efforts to eliminate brain-clogging proteins linked to Alzheimer’s disease.

By tweaking genes in the brains of mice, researchers say they reduced levels of a substance called beta amyloid that’s closely tied to Alzheimer’s.

There’s no guarantee the findings will be relevant to people with Alzheimer’s disease because results of animal studies often aren’t replicated in humans, experts say.

Still, “we can now target amyloids from a different angle,” said study co-author Guojun Bu, a neuroscientist and professor of medicine at the Mayo Clinic in Jacksonville, Fla. The approach “can be explored for Alzheimer’s disease prevention and therapy,” he added.

Clumps of beta-amyloid proteins, known as plaque, are believed to disrupt brain functioning in people with Alzheimer’s disease, the most common form of dementia.

The clumps, which appear to kill brain cells, may develop years before someone shows signs of the progressive brain disease. Some research has suggested that the brains of Alzheimer’s patients can’t easily get rid of the gunk, allowing it to build up and impair their ability to think and move.

In the new study, Bu and colleagues manipulated the genes of mice and removed a gene linked to molecules called heparan sulfates that appear on cell surfaces. The molecules serve a biological purpose, Bu said, but they’ve also been found within clumps of beta amyloid and related “tangles” in the brains of Alzheimer’s patients.

“We found that removing heparan sulfates from the nerve cells vastly reduced amyloids,” he said. And according to Bu, this confirms that the molecules play a role in the formation of the amyloid clumps.

The findings suggest that scientists could reduce levels of the brain-clogging material by disrupting the interaction between the molecules and beta amyloid, Bu said. But this would need to happen without “disturbing the normal biological function.”

Bu said the next step is to look for a compound that can block the molecules and beta amyloid from interacting without hurting the patient. And, “such preclinical studies can takes years before they can be translated to humans,” he explained.

There are other caveats, too. Since it hasn’t been proven that beta amyloid actually causes Alzheimer’s, stopping amyloid production might not necessarily stop the disease. Also, nothing is known about the cost of the approach or side effects.

Bu said any treatment would need to be given in the early days of Alzheimer’s disease before symptoms appear.

Testing could determine whether someone shows signs of early Alzheimer’s disease without obvious symptoms, said study co-author Dr. David Holtzman. He is chair of neurology at Washington University School of Medicine in St. Louis.

Scientists could test the treatment, he said, by giving it to people who don’t exhibit disrupted thinking but do show signs of amyloid buildup. Then, he said, researchers could follow the participants to see if they develop dementia or if the treatment halted Alzheimer’s progression.

Dr. Howard Fillit, executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation, praised the study. “In more sophisticated and modern ways, it confirms previous knowledge” about how the molecules interact with beta amyloid, he said.

However, he cautioned that it’s very difficult to target the molecules in question with medication. Also, since the heparan sulfate molecules bind with other molecules in the body, getting rid of them “could have many effects we don’t know about,” Fillit said.

The study was published March 30 in the journal Science Translational Medicine.

More information

For more about beta amyloid’s role in Alzheimer’s disease, see the Alzheimer’s Association.

---

from Health News / Tips & Trends / Celebrity Health http://ift.tt/1RO36P6

Sweat to Khloé Kardashian’s Fitspirational Playlist

Khloé Kardashian’s Instagram pics alone have become a serious source of fitspiration. And now we can all steal her playlist, and sweat to the same songs that helped Khloe get here:

And here:

And here:

RELATED: Here’s How Khloé Kardashian Works Out 

Well, you get the picture.

The Kocktails with Khloé star and spinning devotee has posted her “spin-spirational” Spotify playlist, filled with gym faves like Beyoncé’s “Run the World.”

“I don’t just love SoulCyle and Cycle House for the workout—for me, spinning is all about the music!” she writes. “The playlist makes or breaks my spin experience. The right songs pump me up, get me in the groove, and make me push through the pain.”

If your spin instructor is open to music suggestions, Khloé suggests taking her playlist to class. Of course, you could always just crank it up while you ride on your own, too—or during any workout for that matter. Because who couldn’t use a little of Khloé’s motivation?

from Health News / Tips & Trends / Celebrity Health http://ift.tt/1TlDYVi

The ‘Not Face’ Needs No Translation

THURSDAY, March 31, 2016 (HealthDay News) — One type of facial expression expresses negative emotion in a wide range of cultures, researchers say.

They found that a furrowed brow, pressed lips and raised chin was interpreted as an expression of negative feelings, such as “I do not agree,” to native speakers of English, Spanish, Mandarin Chinese and American Sign Language.

The Ohio State University team dubbed this expression the “not face.”

The research involved manually tagging images of students speaking, frame by frame, to find which facial muscles were moving and in which directions when they disagreed. Computer algorithms then looked through thousands of resulting frames to find commonalities.

The “not face” that emerged displayed the same three muscle movements: the furrowed brows of “anger,” the raised chin of “disgust” and the pressed-together lips of “contempt,” the researchers said.

They also found that people automatically make this face as if it were part of their spoken or signed language, and that American Sign Language speakers sometimes make the face instead of signing the word “not.”

This is the first time that use of facial expression in American Sign Language has been documented, according to the authors of the study in the May issue of Cognition.

“To our knowledge, this is the first evidence that the facial expressions we use to communicate negative moral judgment have been compounded into a unique, universal part of language,” said Aleix Martinez, a cognitive scientist and professor of electrical and computer engineering.

“Where did language come from? This is a question that the scientific community has grappled with for a very long time,” he said in an Ohio State news release. “This study strongly suggests a link between language and facial expressions of emotion.”

In ongoing research, the team will try to identify other facial expressions, including positive ones, which are used as part of language.

“That will likely take decades,” Martinez said. “Most expressions don’t stand out as much as the ‘not face.'”

More information

The American Psychological Association has more about facial expressions.

---

from Health News / Tips & Trends / Celebrity Health http://ift.tt/1UFBItN

Even Controlled, Epilepsy May Still Cause Problems for Kids

THURSDAY, March 31, 2016 (HealthDay News) — Even when their seizures are well-controlled, children with epilepsy can still have learning and behavioral disorders that lead to social and educational problems when they’re young adults, a new study finds.

“Frequency and intensity of seizures remain important predictors of how well a child does into adulthood. But, somewhat to our surprise we also found seizures are by no means the sole influencers of social and educational outcomes among adults with childhood epilepsy,” said study lead author Anne Berg.

Berg is a scientist with the Ann and Robert H. Lurie Children’s Hospital of Chicago, and professor of pediatrics and neurology at Northwestern University Feinberg School of Medicine.

The research included 241 children and teens in Connecticut who were diagnosed with uncomplicated epilepsy from 1993 to 1997. They were followed for an average of 12 years.

Thirty-nine percent of the participants had excellent seizure control, with no seizures one year after diagnosis, the study showed. About 23 percent had good seizure control, with no seizures up to five years after diagnosis. Nearly 30 percent had seizures that came and went but generally responded to medication, and 8 percent had recurrent, drug-resistant seizures, the study found.

As young adults, more than 90 percent of the participants with excellent seizure control were either pursuing a college degree or had full-time or part-time jobs, compared with 60 percent of those with poor seizure control. More than 90 percent of those with good or excellent seizure control had a driver’s license, compared with 60 percent of those with poor seizure control, researchers said.

Those with a history of learning problems were nearly 50 percent more likely to be unemployed, the study revealed.

Regardless of seizure control, participants with a history of emotional, behavioral or psychiatric conditions such as anxiety, depression, bipolar disorder or attention-deficit/hyperactivity disorder (ADHD) were 60 percent less likely to complete college and 50 percent less likely to be living independently.

Level of seizure control didn’t affect the chances of trouble with the law. Participants with disruptive behavioral disorders, such as oppositional defiant disorder, had a nearly three-times increased risk of trouble with the law, regardless of seizure control.

The findings show the need to screen all children with epilepsy for learning problems, regardless of how well their seizures are controlled, the researchers said. Doing so could help prevent problems later in life.

“Physicians caring for those patients should not assume kids are doing fine just because their seizures are under control. Seizures really don’t tell the whole story,” Berg said in a hospital news release.

The findings were published online recently in the journal Pediatrics.

More information

The U.S. Centers for Disease Control and Prevention has more on epilepsy.

---

from Health News / Tips & Trends / Celebrity Health http://ift.tt/1UFBKBR

Clues to Zika Virus’ Structure May Point to Weaknesses

THURSDAY, March 31, 2016 (HealthDay News) — With the emergence of the Zika virus’ devastating effect on newborns, the race for a vaccine has acquired a new urgency.

Now, U.S. scientists say they’ve uncovered secrets to the germ’s physical structure that might help researchers reach that goal.

“The structure of the virus provides a map that shows potential regions of the virus that could be targeted by a therapeutic treatment, used to create an effective vaccine or to improve our ability to diagnose and distinguish Zika infection from that of other related viruses,” study lead author Richard Kuhn, of Purdue University, said in a university news release.

The mosquito-borne virus — which generally doesn’t cause serious illness in adults — has been associated with thousands of cases, mostly in Brazil, of a severe birth defect called microcephaly. Babies with microcephaly have abnormally small heads, and most wind up with stunted brain development, the U.S. Centers for Disease Control and Prevention said.

Zika infection has also been linked to an increased risk for the autoimmune disease Guillain-Barre syndrome, according to the CDC.

So, the race is on to investigate this otherwise little-understood germ and develop a vaccine to counter its potentially devastating effects.

In their research, Purdue biological scientists Kuhn and Michael Rossmann led a team that mapped the structure of the Zika virus. The two have studied flaviviruses — the family of pathogens to which Zika belongs — for 14 years. They said they were the first to discover the structures of two other flaviviruses, dengue and West Nile.

In the new research, Kuhn and Rossmann collaborated with Theodore Pierson, chief of viral pathology at the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID).

The team focused on a sample of Zika virus taken from a patient infected during an outbreak in French Polynesia. Looking at the virus with “near-atomic resolution,” the researchers discovered that Zika has many chemical and genomic structures that are found in better-known, related viruses such as dengue, West Nile, yellow fever and Japanese encephalitis.

This strong similarity to other flaviviruses is reassuring, Kuhn said, because scientists are already busy looking for vaccines for those pathogens.

However, Zika also differs in key ways from those viruses, the research team noted.

“Most viruses don’t invade the nervous system or the developing fetus due to blood-brain and placental barriers, but the association with improper brain development in fetuses suggest Zika does,” said study co-author and Purdue graduate student Devika Sirohi.

“It is not clear how Zika gains access to these cells and infects them, but these areas of structural difference may be involved. These unique areas may be crucial and warrant further investigation,” Sirohi said.

The scientists uncovered a key spot on the virus’ surface that seems to set Zika apart from other flaviviruses. This projecting structure might act as a unique “lure,” the research team explained, drawing in human cells for contact and infection.

“If this site functions as it does in dengue and is involved in attachment to human cells, it could be a good spot to target an antiviral compound [treatment],” Rossmann said. “If this is the case, perhaps an inhibitor [vaccine] could be designed to block this function and keep the virus from attaching to and infecting human cells.”

The study was funded by NIAID and published online March 31 in the journal Science.

More information

For more on Zika virus, visit the U.S. Centers for Disease Control and Prevention.

---

from Health News / Tips & Trends / Celebrity Health http://ift.tt/1UFBKBH

Fridge-Sized Machine Makes Prescription Drugs ‘On Demand’

By Amy Norton
HealthDay Reporter

THURSDAY, March 31, 2016 (HealthDay News) — Scientists have created a compact machine that can churn out thousands of doses of prescription medication in a day — putting the capabilities of a drug-manufacturing plant into a device the size of a kitchen refrigerator.

Experts said the advance could eventually allow on-the-spot drug production in special circumstances — on the battlefield, during epidemics, after natural disasters, or in cases where a drug is needed for a rare medical condition, for instance.

The research, detailed in the April 1 issue of Science, took a new approach to producing prescription drugs — which, right now, is often an inefficient, time-consuming process.

Chemical engineers at the Massachusetts Institute of Technology (MIT) used so-called “flow technology” to develop a compact machine that can automatically turn raw materials into a finished pharmaceutical-grade medication.

For now, the system is limited to making liquid versions of four common prescription drugs: the antidepressant fluoxetine (Prozac); diphenhydramine hydrochloride, an antihistamine that includes brand-names like Benadryl; the sedative diazepam (Valium); and lidocaine, a widely used local anesthetic.

But the researchers say that drug list can be expanded.

“We’re also working on producing tablets, which are more complicated to manufacture than liquid drug formulations,” said Klavs Jensen, a professor of chemical engineering at MIT who worked on the study.

Other technologies — such as 3D “bioprinters” — could help make that happen, according to Jensen.

Many drug companies are already looking into alternative processing methods — ones that are “continuous” and can be done at one location, Jensen said.

The traditional way of drug-making is similar to cooking, according to Rainer Martin, a senior scientist with drug company Hoffmann-La Roche, in Basel, Switzerland.

Martin, who wrote an editorial published with the study, explained the process this way: Drugs are made in “batches,” and the ingredients — broad groups of chemicals known as reagents, catalysts and solvents — are gradually added into a vat, stirred and heated. Then, the brew is analyzed to see if the chemical reactions are complete.

The problem, Jensen said, is that batch manufacturing has “little flexibility to respond to surges in demand” — such as epidemics. Plus, he added, there can be “severe disruptions” in the drug supply if one plant has to shut down.

The compact system his team developed is continuous, Jensen explained. Chemical reactions take place as chemicals flow through small tubes, instead of sitting in large vats.

The result, according to Martin, is that complex and “laborious” drug-making steps are all done in “fully automated fashion.”

Martin said he could envision the compact system being used in a number of scenarios: During a disease outbreak in a refugee camp or remote area, for example, or by individual hospitals that need large amounts of a particular drug on a regular basis.

Matthew Osterhaus, immediate past president of the American Pharmacists Association, agreed that the technology might prove useful in special circumstances.

As an example, he pointed to “orphan drugs” — medications used to treat rare diseases. “Let’s say there’s a condition that’s treated at five medical centers in the U.S.,” Osterhaus said. “It’s possible those hospitals would be able to use this.”

When it comes to everyday health care, though, it’s difficult to see how an appliance-sized drug machine could fit in, according to Osterhaus. As a pharmacist, he said, he has access to about 6,000 drugs right now.

“So it’s a stretch to see how this could change my practice,” Osterhaus said.

Jensen agreed that the technology could be used in specialized cases, like humanitarian crises and orphan-drug production — since “small-volume” batch processing is usually not cost-effective for large plants.

And then there’s the potential for battlefield use. Jensen said “national defense needs” are what spurred the quest for such a compact system: The research was funded by the Defense Advanced Research Project Agency, which is aiming to fortify medical care available on the front lines.

But Jensen said he also envisions larger health systems, like a hospital network or a health plan, being able to manufacture their own drugs.

Martin went deeper into visionary territory — seeing a future where people can use smartphone apps and a microwave-sized device to cook up an antibiotic for their feverish toddler (in consultation with a doctor).

But that, he stressed, won’t be happening any time soon.

For now, there are more pressing issues, according to Martin. One is how the raw materials for making the drugs would be delivered: “Would it be, for example, in the way of cartridges, similar to ink for inkjet printers?” he said.

And at the other end of the process, Martin said, there would have to be ways to safely dispose of waste products.

More information

The U.S. Food and Drug Administration has more on how drugs are developed.

---

from Health News / Tips & Trends / Celebrity Health http://ift.tt/1ZOba8y

Diabetes Meds Vary in Safety and Effectiveness, Study Shows

THURSDAY, March 31, 2016 (HealthDay News) — A study of nearly a half-million people with type 2 diabetes shows there are pros and cons to nearly every form of drug therapy for the disease.

In the British study, researchers looked at patient outcomes from a large U.K. database of almost 470,000 adults with type 2 diabetes, tracked between 2007 and 2015.

Julia Hippisley-Cox and Carol Coupland, of the University of Nottingham, sought to parse out differences among a variety of diabetes drugs. They accounted for complicating patient factors such as age, sex, smoking and poverty, as well as how long a person had been diagnosed with type 2 diabetes.

The researchers also focused on five major outcomes linked to diabetes: blindness, amputation, severe kidney failure, and high or low blood sugar.

Reporting March 30 in BMJ, they found that when a class of drugs called glitazones (Actos, Avandia) was prescribed along with the standard diabetes drug metformin, there was a higher risk for kidney failure than with metformin alone.

The same was true when another class of meds called gliptins (Januvia, Onglyza and others) was combined with metformin.

However, there were “up” sides to these drug combos as well. People who took a gliptin or a glitazone plus metformin had “significantly lower” risks for high blood sugar than those who took metformin alone, the research found.

Finally, the study looked at “triple” therapy: patients taking metformin, a gliptin or a glitazone, and a sulphonylurea, another type of diabetes drug. This combination was linked to “significantly higher” odds for episodes of potentially dangerous low blood sugar, the British researchers said, compared to people taking metformin alone.

On the other hand, triple-therapy users had a reduced risk for diabetes-linked blindness, compared to the metformin-only group.

The study doesn’t establish direct cause-and-effect relationships between the various drugs and these outcomes. Still, according to experts, the findings support the notion that diabetes care is never a “one-size-fits-all” endeavor.

“There are many treatment options for diabetes — they have the benefit of lowering blood sugar levels, but they also carry risk,” said Dr. Robert Courgi, an endocrinologist at Northwell Health’s Southside Hospital in Bay Shore, N.Y.

He said that standard guidelines typically list metformin as a first-line therapy against type 2 disease, but additional drugs may be needed. “Ultimately, the physician and the patient need to work together to find the best treatment possible,” Courgi said.

Dr. Gerald Bernstein coordinates the Friedman Diabetes Program at Lenox Hill Hospital in New York City. He believes the field of diabetes care is constantly evolving.

“Treating type 2 diabetes used to be like a singles pingpong game — give a pill, lower blood sugar,” he said.

However, “over the last 75 years or so we have learned that it is more of a team effort, because the process of safely lowering blood sugar is more complicated than previously thought,” Bernstein explained. “The goal of treatment for all diabetes is to prevent complications and have a high quality of life.”

Different medications have different targets and effects, he said, and “the art of treatment today mixes and matches these medications depending on age, weight, activity.”

More information

For more on the treatment of type 2 diabetes, head to the American Diabetes Association.

---

from Health News / Tips & Trends / Celebrity Health http://ift.tt/1ZObcgQ

‘Listeria on Rye’? Many U.S. Deli Meat Slicers Cut Corners on Cleanliness

THURSDAY, March 31, 2016 (HealthDay News) — The next time you sidle up to the deli counter for a sandwich, you may want to think about how often the meat slicer gets cleaned.

That’s because a new federal government survey of a sample of delis across the United States found that about half fail to clean their slicing equipment every four hours, as recommended.

Leaving machines cleaned and unsterilized for longer than four hours raises the odds for potentially deadly listeria, according to the report released Thursday by the U.S. Centers for Disease Control and Prevention.

“Meats sliced and packaged at retail delis are the major source of listeriosis illnesses” because of the potential for cross-contamination, a team led by researcher Laura Brown said in the report.

The CDC notes that infection with the listeria bacterium is the third largest cause of deaths linked to food-borne illness in the United States. Each year, about 255 Americans will die from the illness.

Since meat slicers are a potential breeding ground for listeria, Brown’s team asked managers and workers at 298 randomly selected delis across the country about their daily safety measures.

The researchers noted that only 43 percent of the nearly 700 deli managers contacted in California, Minnesota, New York, New York City, Rhode Island and Tennessee agreed to be part of the survey.

Interviews with the managers and staff at the delis that did agree to the survey found that “approximately half of delis fully cleaned their slicers less often than the FDA’s specified minimum frequency” of every four hours, Brown’s team reported.

Deli chains seemed to be more likely to adhere to the 4-hour rule than independent outlets, the study found. And — perhaps unexpectedly — busier delis were actually more likely to be fastidious about cleaning the slicer than delis with a lower customer turnover.

Other things to look for when assessing whether your local deli is cleaning meat slicers on time:

• Multiple slicers — having more of the machines upped the chances they were cleaned regularly. And slicers deemed “easy to clean” by workers also raised cleaning rates, the CDC said.
• More workers per shift, plus a food safety training program for both management and workers.
• Higher turnover of meat products per day.
• Having written slicer-cleaning policies in place.

The CDC researchers noted that the problem may even be more widespread than the survey picked up, because of “social desirability bias” — respondents giving investigators answers that reflected well on their particular deli.

What to do? Brown’s team said education is key to improving deli safety, and “because frequencies of slicer cleaning were lower at independent and smaller delis, prevention efforts should focus on these types of establishments.”

The study was published in the April 1 issue of the CDC’s journal Morbidity and Mortality Weekly Report.

More information

Find out how you can avoid foodborne illness at the U.S. Food and Drug Administration.

---

from Health News / Tips & Trends / Celebrity Health http://ift.tt/1UFBId4

U.S. Autism Rate Unchanged at 1 in 68 Kids: CDC

THURSDAY, March 31, 2016 (HealthDay News) — The autism rate among school-aged children in the United States has held steady in recent years, but it’s too early to determine whether rates are stabilizing, according to a federal government report released Thursday.

The autism rate was 1 in 68 children in 2012, the same as it was in 2010, according to the latest data from the U.S. Centers for Disease Control and Prevention.

The CDC gets its numbers from monitoring autism among 8-year-olds in 11 communities in Arizona, Arkansas, Colorado, Georgia, Maryland, Missouri, New Jersey, North Carolina, South Carolina, Utah and Wisconsin.

“What we know for sure is that there are many children living with autism who need services and support now and as they grow into adolescence and adulthood,” Dr. Stuart Shapira, chief medical officer for the CDC’s National Center on Birth Defects and Developmental Disabilities, said in an agency news release.

One expert has a theory as to why the numbers haven’t budged since 2010.

“This probably reflects the fact that screening methods — which have been implemented in pediatric primary care as well as in early childhood centers — are identifying the correct number of children,” said Dr. Ron Marino, associate chair of pediatrics at Winthrop-University Hospital in Mineola, N.Y.

He believes that, prior to 2010, there was a “learning curve” among doctors when it came to properly diagnosing autism spectrum disorders.

The CDC noted that autism rates varied widely between communities.

For example, black and Hispanic children are less likely to be identified with autism, or they receive development evaluations later, compared to white children, the agency said.

Better, targeted methods are needed to spot minority kids with autism and make sure they are “connected to the services they need,” said study lead author Daisy Christensen, a CDC epidemiologist.

She and her colleagues also found that only 43 percent of children identified with autism receive developmental evaluations by age 3. That suggests that many kids with autism may not be identified as early as they could be.

“The most powerful tool we have right now to make a difference in the lives of children with (autism) is early identification,” Shapira said.

“Parents, childcare professionals and doctors can monitor each child’s development and act right away on any developmental concerns,” he added. “It’s important to remember that children can be connected to services even before an official diagnosis is made.”

Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Cohen Children’s Medical Center in New Hyde Park, NY., said the new report offered some good news.

“For many years, it seemed that the prevalence of autism spectrum disorders was consistently rising; it is encouraging that this trend has ceased and that the prevalence of autism spectrum disorders has not increased in the past two years,” he said.

But, he added, “the rate remains alarmingly high.”

And he agreed that parents should remain vigilant to spot symptoms of autism early on in their children.

“If parents have concerns about the language development, eye contact or social responsiveness of their toddler or preschooler, they should discuss their concerns with their pediatrician and seek out a developmental evaluation,” Adesman said.

The CDC report was published March 31 in the agency’s journal, Morbidity and Mortality Weekly Report.

More information

The National Alliance on Mental Illness has more about autism.

---

from Health News / Tips & Trends / Celebrity Health http://ift.tt/1UFBHWD